---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-047916"
form_type: "8-K"
ticker: "VRDN"
cik: "0001590750"
company_name: "Viridian Therapeutics, Inc.\\DE"
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T11:53:25.992335+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Viridian reports $645.7M cash, $237.7M net loss; VRDN-001 Phase 3 readouts mid-2024

## Summary
- Cash, cash equivalents and short-term investments ~$645.7M as of Jan 31, 2024 (preliminary), extending runway into H2 2026.
- Net loss for FY2023 was $237.7M vs $129.9M in 2022; R&D expenses rose to $159.8M.
- VRDN-001 Phase 3 THRIVE topline data expected mid-2024; THRIVE-2 at year-end 2024.
- VRDN-003 subcutaneous pivotal program expected to start mid-2024 pending regulatory alignment.
- FcRn inhibitor VRDN-006 IND submission anticipated by year-end 2024; VRDN-008 NHP data H2 2024.

## SEC filing metadata
- accession: 0001193125-24-047916
- form_type: 8-K
- ticker: VRDN
- cik: 0001590750
- company_name: Viridian Therapeutics, Inc.\DE
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1590750/000119312524047916/0001193125-24-047916-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1590750/000119312524047916/d802648d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-047916
- JSON: https://secwatch.observer/filing/0001193125-24-047916.json
- Plain text: https://secwatch.observer/filing/0001193125-24-047916.txt

## Key facts
- Earnings Releases
  Viridian Therapeutics, Inc.\DE reported preliminary financial results for the fourth quarter and year ended December 31, 2023.
  - Period: the fourth quarter and year ended December 31, 2023
  - Result: preliminary results
  source text: Viridian Therapeutics, Inc. (the “Company”) issued a press release reporting financial results for the fourth quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1590750/000119312524047916/0001193125-24-047916-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.